WASHINGTON, DC—(Marketwired – May 01, 2015) – Mallinckrodt Pharmaceuticals (NYSE: MNK) will join the Lupus Foundation of America in its efforts to end the cruel mystery of lupus by sponsoring its signature program, Walk to End Lupus Nowâ„¢. Walk events take place in more than 60 cities across the country, making it the nation's largest lupus walk program. The national sponsorship, a first–of–its–kind for the Lupus Foundation of America, will raise money for lupus research and education programs, and support its mission to improve the quality of life for all people affected by lupus.
Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body. The walk events
bring together community members — people with lupus, friends, families, health care providers, and celebrities — to raise money for lupus research and education programs, increase awareness of the disease, and rally public support for those who feel the brutal impact of lupus.Â
“We would like to thank Mallinckrodt for their generous support as a new national sponsor of Walk to End Lupus Now, as well as their ongoing commitment to lupus research and patient education to help the 1.5 million Americans living with this disease,” said Donna Grogan, Vice President of Development and Fundraising for the Lupus Foundation of America.
“Raising awareness, prevention and treatment of lupus, a debilitating and very destructive disease, is very important. Mallinckrodt supports advocacy events and helps educate patients with tools on how to keep up the fight and manage lupus,” said Derek Naten, Senior Director, Government Affairs and Advocacy Relations. “We are proud to support an organization like the Lupus Foundation of America that continues to make great strides in combating lupus by educating, supporting and advocating for patients and others affected.”
Registration for the Walk is open online at WalkToEndLupus.org or by calling 877–910–9779. Participants can also create a personal fundraising page on the Walk website to raise money, recruit new team members, and get valuable fundraising tips.
About Lupus
Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body. It is difficult to diagnose, hard to live with and a challenge to treat. Lupus is a cruel mystery because it is hidden from view and undefined, has a range of symptoms, strikes without warning, and has no known cause and no known cure. Its health effects can range from a skin rash to a heart attack. Lupus is debilitating and destructive and can be fatal, yet research on lupus remains underfunded relative to diseases of similar scope and devastation.Â
About the Lupus Foundation of America
The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world's cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus. Learn more about the Lupus Foundation of America at lupus.org. For the latest news and updates, follow us on Twitter and Facebook.
About Mallinckrodt
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office– and hospital–based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and devices; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
The following files are available for download:
LFALogoLock–up 2C ClearSpace RGB